News
Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease. The clinical-stage biotech company said the study ...
Stockhead on MSN9mon
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study
Tryptamine’s phase 1b study of IV-infused psilocin meets all objectives Lead asset TRP-8803 found safe at low, mid and upper ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback